PURPOSE: Differentiation between bacterial infection and nonbacterial inflammation remains a diagnostic challenge. Vascular adhesion protein 1 (VAP-1) is a human endothelial protein whose cell surface expression is induced under inflammatory conditions, thus making it a highly promising target molecule for studying inflammatory processes in vivo. We hypothesized that positron emission tomography (PET) with gallium-68-labeled 1,4,7,10-tetraazacyclododecane-N',N'',N''',N''''-tetraacetic acid-peptide targeted to VAP-1 ((68)Ga-DOTAVAP-P1) could be feasible for imaging the early inflammatory and infectious processes in healing bones. MATERIALS AND METHODS: Thirty-four Sprague-Dawley rats with diffuse Staphylococcus aureus tibial osteomyelitis and 34 rats with healing cortical bone defects (representing the inflammation stage of healing) were PET imaged using (68)Ga-DOTAVAP-P1 as a tracer. In addition, peripheral quantitative computed tomography and conventional radiography were performed. Bone samples for quantitative bacteriology and specimens were also processed for histomorphometry of inflammatory and infectious reactions. RESULTS: PET imaging showed an uptake of (68)Ga-DOTAVAP-P1 in both the osteomyelitic bones and the healing cortical bone defects during the first 36 h after surgery. Thereafter, only the osteomyelitic tibias were delineated by PET. The osteomyelitic and control animals showed a similar uptake of the (68)Ga-DOTAVAP-P1 at 24 h, whereas a significant difference was observed at 7 days (p < 0.0001). CONCLUSIONS: The current study showed that PET imaging with the new (68)Ga-DOTAVAP-P1 is capable of accurately demonstrating the phase of inflammation in healing bones and the progress of bacterial infection in osteomyelitic bones. Consequently, this novel imaging agent allowed for the differentiation of bone infection due to S. aureus and normal bone healing as soon as 7 days after onset.
PURPOSE: Differentiation between bacterial infection and nonbacterial inflammation remains a diagnostic challenge. Vascular adhesion protein 1 (VAP-1) is a human endothelial protein whose cell surface expression is induced under inflammatory conditions, thus making it a highly promising target molecule for studying inflammatory processes in vivo. We hypothesized that positron emission tomography (PET) with gallium-68-labeled 1,4,7,10-tetraazacyclododecane-N',N'',N''',N''''-tetraacetic acid-peptide targeted to VAP-1 ((68)Ga-DOTAVAP-P1) could be feasible for imaging the early inflammatory and infectious processes in healing bones. MATERIALS AND METHODS: Thirty-four Sprague-Dawley rats with diffuse Staphylococcus aureus tibial osteomyelitis and 34 rats with healing cortical bone defects (representing the inflammation stage of healing) were PET imaged using (68)Ga-DOTAVAP-P1 as a tracer. In addition, peripheral quantitative computed tomography and conventional radiography were performed. Bone samples for quantitative bacteriology and specimens were also processed for histomorphometry of inflammatory and infectious reactions. RESULTS: PET imaging showed an uptake of (68)Ga-DOTAVAP-P1 in both the osteomyelitic bones and the healing cortical bone defects during the first 36 h after surgery. Thereafter, only the osteomyelitic tibias were delineated by PET. The osteomyelitic and control animals showed a similar uptake of the (68)Ga-DOTAVAP-P1 at 24 h, whereas a significant difference was observed at 7 days (p < 0.0001). CONCLUSIONS: The current study showed that PET imaging with the new (68)Ga-DOTAVAP-P1 is capable of accurately demonstrating the phase of inflammation in healing bones and the progress of bacterial infection in osteomyelitic bones. Consequently, this novel imaging agent allowed for the differentiation of bone infection due to S. aureus and normal bone healing as soon as 7 days after onset.
Authors: Tatu J Mäkinen; Petteri Lankinen; Tiina Pöyhönen; Jari Jalava; Hannu T Aro; Anne Roivainen Journal: Eur J Nucl Med Mol Imaging Date: 2005-07-09 Impact factor: 9.236
Authors: Craig M Stolen; Fumiko Marttila-Ichihara; Kaisa Koskinen; Gennady G Yegutkin; Raisa Turja; Petri Bono; Mikael Skurnik; Arno Hänninen; Sirpa Jalkanen; Marko Salmi Journal: Immunity Date: 2005-01 Impact factor: 31.745
Authors: T Kon; T J Cho; T Aizawa; M Yamazaki; N Nooh; D Graves; L C Gerstenfeld; T A Einhorn Journal: J Bone Miner Res Date: 2001-06 Impact factor: 6.741
Authors: Filip Gemmel; Hans Van den Wyngaert; Charito Love; M M Welling; Paul Gemmel; Christopher J Palestro Journal: Eur J Nucl Med Mol Imaging Date: 2012-02-24 Impact factor: 9.236
Authors: Anu Autio; Tiina Ujula; Pauliina Luoto; Satu Salomäki; Sirpa Jalkanen; Anne Roivainen Journal: Eur J Nucl Med Mol Imaging Date: 2010-06-04 Impact factor: 9.236
Authors: Jaime Retamal; Jens Sörensen; Mark Lubberink; Fernando Suarez-Sipmann; João Batista Borges; Ricardo Feinstein; Sirpa Jalkanen; Gunnar Antoni; Göran Hedenstierna; Anne Roivainen; Anders Larsson; Irina Velikyan Journal: Am J Nucl Med Mol Imaging Date: 2016-01-28